Quince Therapeutics Inc. (QNCX)
Quince Therapeutics Statistics
Share Statistics
Quince Therapeutics has 44M shares outstanding. The number of shares has increased by 2.64% in one year.
| Shares Outstanding | 44M |
| Shares Change (YoY) | 2.64% |
| Shares Change (QoQ) | 1.68% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 32.66M |
| Failed to Deliver (FTD) Shares | 2.06K |
| FTD / Avg. Volume | 1.37% |
Short Selling Information
The latest short interest is 2.35M, so 5.33% of the outstanding shares have been sold short.
| Short Interest | 2.35M |
| Short % of Shares Out | 5.33% |
| Short % of Float | 7.15% |
| Short Ratio (days to cover) | 2.27 |
Valuation Ratios
The PE ratio is -1.25 and the forward PE ratio is -5.16. Quince Therapeutics's PEG ratio is 0.03.
| PE Ratio | -1.25 |
| Forward PE | -5.16 |
| PS Ratio | 0 |
| Forward PS | 0.3 |
| PB Ratio | 0.46 |
| P/FCF Ratio | -2.12 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Quince Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.16.
| Current Ratio | 8.09 |
| Quick Ratio | 8.09 |
| Debt / Equity | 0.16 |
| Total Debt / Capitalization | 13.97 |
| Cash Flow / Debt | -1.32 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.37% and return on capital (ROIC) is -34.79%.
| Return on Equity (ROE) | -0.37% |
| Return on Assets (ROA) | -0.19% |
| Return on Capital (ROIC) | -34.79% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-980,781.25 |
| Employee Count | 32 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -197K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 24.79% in the last 52 weeks. The beta is 0.61, so Quince Therapeutics's price volatility has been higher than the market average.
| Beta | 0.61 |
| 52-Week Price Change | 24.79% |
| 50-Day Moving Average | 1.63 |
| 200-Day Moving Average | 1.15 |
| Relative Strength Index (RSI) | 46.1 |
| Average Volume (20 Days) | 150.9K |
Income Statement
| Revenue | n/a |
| Gross Profit | -322K |
| Operating Income | -34.62M |
| Net Income | -31.39M |
| EBITDA | -31.26M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.84 |
Balance Sheet
The company has 20.75M in cash and 13.81M in debt, giving a net cash position of 6.94M.
| Cash & Cash Equivalents | 20.75M |
| Total Debt | 13.81M |
| Net Cash | 6.94M |
| Retained Earnings | -319.64M |
| Total Assets | 126.52M |
| Working Capital | 46.29M |
Cash Flow
In the last 12 months, operating cash flow was -18.29M and capital expenditures -160K, giving a free cash flow of -18.45M.
| Operating Cash Flow | -18.29M |
| Capital Expenditures | -160K |
| Free Cash Flow | -18.45M |
| FCF Per Share | -0.5 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -57.53% |
| FCF Yield | -28.72% |
Analyst Forecast
The average price target for QNCX is $11, which is 653.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $11 |
| Price Target Difference | 653.4% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -4.07 |
| Piotroski F-Score | 2 |